文献速递瓣膜病与结构性心脏病

低危主动脉瓣狭窄患者TAVR与外科换瓣5年结局对比

5-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis.
PubMed 文献 · J Am Coll Cardiol · 2025-03-30

Evolut Low Risk试验将1414例低危重度主动脉瓣狭窄患者随机分配至经导管主动脉瓣置换(TAVR)或外科换瓣,5年时全因死亡或致残性卒中复合终点在两组间无显著差异(15.5% vs 16.4%,P=0.47),瓣膜耐久性和生活质量两组均良好。

要点

  • 低危重度主动脉瓣狭窄患者5年全因死亡或致残性卒中TAVR不劣于外科换瓣。
  • 5年全因死亡、致残性卒中、心血管死亡及非心血管死亡两组均无显著差异。
  • 5年瓣膜再干预率两组均较低且无显著差异,生活质量持续改善。

核心结论

  • 5年时低危重度主动脉瓣狭窄患者接受TAVR或外科换瓣的全因死亡或致残性卒中发生率相当,瓣膜耐久性与性能两组均优良,支持TAVR在此人群不劣于外科换瓣。

研究设计与样本

  • Evolut Low Risk试验为随机对照研究,共1414例低危重度主动脉瓣狭窄患者接受尝试性植入(TAVR组730例,外科组684例),平均年龄74岁(范围51-88岁),女性占35%。

主要发现

  • 5年Kaplan-Meier估计全因死亡或致残性卒中复合终点TAVR组15.5%、外科组16.4%(P=0.47)。
  • 5年全因死亡TAVR组13.5%、外科组14.9%(P=0.39),致残性卒中3.6% vs 4.0%(P=0.57)。
  • 5年心血管死亡TAVR组7.2%、外科组9.3%(P=0.15),非心血管死亡6.8% vs 6.2%(P=0.73)。
  • 对失访或退出患者补充中心层面生命状态查询后,5年全因死亡率TAVR组14.7%、外科组15.2%(P=0.74)。
  • 5年瓣膜再干预率TAVR组3.3%、外科组2.5%(P=0.44),两组堪萨斯城心肌病问卷汇总评分分别为88.3±15.8和88.5±15.8。

临床怎么用

  • 对于低外科风险的严重主动脉瓣狭窄患者,TAVR可作为与外科换瓣相当的选项,5年死亡与卒中结局相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Evolut Low Risk trial demonstrated that transcatheter aortic valve replacement (TAVR) was noninferior to surgery for the primary endpoint of all-cause mortality or disabling stroke at 2 years. Outcomes at 5 years have not been reported. OBJECTIVES: This study sought to evaluate 5-year clinical and hemodynamic outcomes with TAVR vs surgery in patients from the Evolut Low Risk trial. METHODS: We randomly assigned low-risk patients with severe aortic stenosis to TAVR or surgery. The primary endpoint was a composite of all-cause mortality or disabling stroke. Secondary endpoints included clinical, echocardiographic, and quality-of-life outcomes through 5 years. RESULTS: A total of 1,414 patients underwent an attempted implant (n = 730 TAVR, n = 684 surgery). The mean age was 74 years (range 51-88 years), and women accounted for 35% of patients. At 5 years the Kaplan-Meier estimate for the primary endpoint of all-cause mortality or disabling stroke was 15.5% for the TAVR group and 16.4% for the surgery group (P = 0.47). The Kaplan-Meier estimates in the TAVR and surgery groups for all-cause mortality were 13.5% and 14.9% (P = 0.39) and for disabling stroke were 3.6% and 4.0% (P = 0.57). Cardiovascular mortality was 7.2% in the TAVR group and 9.3% in the surgery group (P = 0.15). Noncardiovascular mortality in the TAVR group was 6.8% and 6.2% in the surgery group (P = 0.73). A site-level vital status sweep was performed for patients who were lost to follow-up or withdrew from the study. With the addition of these patients, the all-cause mortality rate at 5 years for patients undergoing TAVR was 14.7% and for surgery was 15.2% (P = 0.74). Over 5 years, valve reintervention rate was 3.3% for TAVR and 2.5% for surgery (P = 0.44). A sustained improvement in quality of life was observed in both treatment arms with mean Kansas City Cardiomyopathy Questionnaire summary score of 88.3 ± 15.8 in TAVR and 88.5 ± 15.8 in surgery. CONCLUSIONS: At 5 years, patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke. Valve durability and performance were excellent in both arms. This midterm evaluation reinforces the position of TAVR as noninferior to surgery in patients with severe aortic stenosis at low surgical risk (Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients; NCT02701283).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Forrest JK, Yakubov SJ, Deeb GM, et al. 5-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis. J Am Coll Cardiol. 2025. PMID: 40158212. doi:10.1016/j.jacc.2025.03.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。